AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long (NYSE:AZN)
· seekingalpha.com
AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.
Hey this is Sam, an independent investor with a degree in Finance from the University of Oklahoma. I have been investing my own money for several years, with a ...